 |
|
|
Agenda Information
Click here to download a copy of the Advanced Program.
Thursday
Friday
Saturday
|
|
Thursday Night
|
|
|
5:00 - 8:00 pm
|
Registration and Check-in
Spangler Center, HBS Campus
(Registration and check-in will continue throughout the conference)
|
|
|
6:00 pm
|
Welcome Reception and Dinner
Back to Top
Welcome Back to HBS
Bunny Ellerin, MBA 95
President & Founder, HBS Health Industry Alumni Association
Gary Pisano, PhD
Professor, Harvard Business School
|
|
Back to Top
Friday
|
|
|
|
7:45 - 8:45 am
|
Breakfast Roundtable Discussions
Spangler Center, HBS Campus
Attendees will self-select according to area of interest to discuss a specific healthcare topic over breakfast.
|
|
|
|
9:00 - 9:15 am
|
Opening Remarks & Welcome
Robert DeNoble, MBA '72
Conference Co-Chair
Wolfgang Klietmann, MD, OPM 12
Conference Co-Chair
|
|
|
|
9:15 - 10:30 am
|
Disruptive Innovations in Healthcare
Clayton Christensen, PhD, MBA 79
Professor, Harvard Business School
Disruptive innovations are simpler, more convenient, and less costly offerings initially designed to appeal to the low end of the market. Over time, they gradually improve to meet the needs of the vast majority of users, and eventually take over the market. Professor Christensen will discuss how the use of disruptive innovation theory could transform the healthcare industry by allowing consumers to have less-expensive, simpler, more convenient access to quality care.
|
|
|
|
10:30 10:45 am
|
Coffee Break
|
|
|
|
10:45 11:45 am
|
Medical Device Selling Models, Elliot Spitzer, and Other Random Thoughts
Glenn Reicin, MBA 90
Managing Director, Morgan Stanley
Wall Street Analyst Glenn Reicin reviews various selling models of hospital supply and medical device companies, along with the importance of technology, sales force relationships, and hospital buying behavior on growth of various market segments. Mr. Reicin believes that several of these selling models are built on generally accepted business practices which may be scrutinized in future years as buyers become more concerned about cost containment. Further, unless the industry polices itself more aggressively and also relies more on technology advances to create value for its customers, these practices could be subject to increased scrutiny from the likes of Elliot Spitzer, potentially changing the economics of the medical device industry.
|
|
|
|
11:45 am 1:00 pm
|
Luncheon, concurrent with Deans Address
Kim B. Clark, PhD
Dean of the Faculty, Harvard Business School
|
|
|
|
1:00 2:15 pm
|
Roundtable Discussions
Attendees will self-select according to area of interest to discuss a specific healthcare topic.
|
|
|
|
2:15 3:15 pm
|
Shaking Up the Health Insurance Industry:
Launching New Models That Threaten Managed Care
Stephen F. Wiggins, MBA 84
Founder, Chairman, and CEO, HealthMarket
As recently as the 1980s, managed care was viewed by many large insurance companies as a harmless threat to their health insurance business. Behemoths like Travelers, Metropolitan, and New York Life were once dominant players in health insurance but they were slow to adopt the radically different business model of managed care. Ultimately, their business was hammered by the fledgling HMO start-ups. Today, managed care companies dominate health insurance, and are themselves scoffing at new models of health insurance that have launched in many markets. Some of these new models are now proving to achieve cost levels 10% to 25% below managed care for the same benefits. This session will provide case studies that naturally beg the question of whether the same fate awaits the laggards of the managed care industry.
|
|
|
|
3:15 - 3:45 pm
|
Coffee Break
|
|
|
|
3:45 - 5:00 pm
|
Changing Models of Healthcare Delivery
Richard Bohmer, MD, MPH
Assistant Professor, Technology and Operations Management, Harvard Business School
The knowledge base for delivering medical care has expanded exponentially. Patients have taken greater control of their care by easily obtaining up-to-date information from the Internet and other sources; alternative and complementary treatments have been integrated with traditional modes of care; and medical technology has provided caregivers with more sophisticated tools for diagnosis and treatment. This session will address the impact that these forces have on the future of healthcare delivery.
|
|
|
|
5:00 - 6:00 pm
|
Harnessing Technology in Health Care
David Cutler, PhD
Professor of Economics and Associate Dean, Faculty of Arts and Sciences for Social Sciences, Harvard University
Technological change is frequently invoked as harmful in health care driving up costs, causing more people to be uninsured, and leading to medical errors. While all these are often true, technology has also brought enormous benefits in terms of longer, higher quality lives. Professor Cutler discusses these dual features of medical technology, and demonstrates how changing the reimbursement environment into which technology is introduced will allow medical technology to be a solution to health care problems.
|
|
|
|
6:00 - 8:00 pm
|
Cocktails & Dinner on HBS Campus
|
|
|
|
8:00 pm
|
Dinner Presentations:
Catalyzing Harvard University to Tackle Global Health Challenges
Christopher Murray, MD, PhD
Director, Global Health Initiative, Harvard University
Global health presents an interdisciplinary set of challenges. Current boundaries between disciplines, sectors, institutions, and geographic locations must be crossed to enable a meaningful response to these grand challenges. This session seeks to contribute to the creation of a new generation of leaders for global health, and to bridge the gap from basic to applied life sciences, including social, economic, political, and ethical issues in order to develop new and innovative solutions to the vital problems of global health.
Healthcare Philanthropy: Feeling Good or ROI?
Joseph Saba, MD
Chief Executive Officer, Axios International
With globalization, the need to do good has spread to poor countries on the five continents and is particularly acute in health care. Since this is a recent trend, there are no standards on how philanthropy should be managed and how we can measure the effect on the business. Dr. Saba will examine three issues:
- Why should a company seek to do good in poor countries with small markets?
- What value does it bring shareholders? Should shareholders donate as individuals or have a company use their money to do so? Does philanthropy simply enable top management to feel good? Or is this part of the agency cost of running a corporation? What is the added value of corporate philanthropy versus international aid from rich governments?
- How can we assess and measure ROI with philanthropy? Where does it fit within corporate social responsibility?
|
|
|
Back to Top
Saturday
|
|
|
|
8:30 9:45am
|
Case Study:
The Power of Direct-to-Consumer Drug Advertising
Marta Wosinska, PhD
Assistant Professor, Harvard Business School
The changing regulatory environment and increasing involvement of patients in their health care have altered the marketing strategies of drug manufacturers. Drug marketers no longer solely focus on physicians but also increasingly consider the role of the patient in driving their sales. Using the case study of Propecia, this session will explore what drives the return-on-investment for direct-to-consumer advertising.
In late 1997, Tom Casola, the brand manager for Propecia, is debating the best approach to market this breakthrough drug for hair loss. Although drugs have traditionally been marketed to physicians, recent regulatory changes have made marketing directly to consumers more feasible. The regulations, however, require that side effects be listed if the ad mentions both brand name and its indication. Tom must now make some key decisions: (1) decide whether the ads contain brand name, indication, or both, (2) decide how to set appropriate expectations for the product's performance, and (3) determine how much support is needed through physician marketing.
|
|
|
|
9:45 - 10:00 am
|
Coffee Break
|
|
|
|
10:00 - 11:30 am
|
The Biotech Model: Profiting through Partnerships with Pharma
Geoffrey Duyk, MD, PhD
Managing Director, TPG Ventures
Gail Maderis, MBA 85
President and Chief Executive Officer, FivePrime Therapeutics
The latter half of the 20th century witnessed the transformation of our fundamental understanding of biology and medicine, as potentially disruptive as the similar revolution that occurred in the world of physics in the first half of the century. In the wake of the human genome project, which history may view as the "end of the beginning" for this phase of biomedical research, we are also witnessing fundamental change in the culture of how we do both fundamental and translational research. From a commercial perspective, it is likely that our expectation of the commercial potential of these fundamental changes was both oversold and currently under-appreciated. Our session seeks to explore how we can evolve the business expectations and models for underwriting a successful biotechnology company.
|
|
|
|
11:30 am- 12:45 pm
|
Pay for Performance Contracting:
New Business Model or Latest Fad?
Charles D. Baker
President and Chief Executive Officer, Harvard Pilgrim Health Care
Robert Galvin, MD
Director of Global Health Care, General Electric
Moderator:
David Terry, MBA 98
Senior Vice President, Harborside Healthcare
Pay for Performance is emerging as a new, hot contracting mechanism between providers, plans, and employers. The goal of these contracts is to provide direct and clear incentives for quality and efficiency. Bob Galvin and GE have been a major driver of this trend through Bridges to Excellence, The Leapfrog Group, and other vehicles. Charlie Baker is CEO of one of the first plans in the country to enter into a live Pay for Performance deal. In this session, Bob and Charlie will offer their perspectives on the value of this contracting method, how and why it's displacing capitation, the impact it has had to date, and where it's likely to go from here.
|
|
|
|
12:45 - 2:00 pm
|
Luncheon, concurrent with Interactive Thought Leadership Session
In association with leading consultancy PRTM, HBS Health will query attendees about key issues affecting the healthcare industry. PRTM executives will lead a group discussion based on the answers provided. The use of instant response technology is made possible through RSi Communications
|
|
|
|
2:00 3:00 pm
|
Closing Remarks & Networking
|
|
|
Back to Top
|
|
